ADAP News and Press, Adaptimmune Therapeutics plc From 10/21/21

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US mar...

- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - - The Company will host its first virtual medical symposium at CTOS - - Translational data from Phase 1 SURPASS trial to be presented at SITC - P...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval. Current valuation is fair given their market cap and pipeline, but longer-term outlook remains bullish. F...

In an about-face from its impressive performance last week, Adaptimmune Therapeutics (NASDAQ: ADAP) stock declined by nearly 14% over the past five trading days. This occurred even though the cancer-focused biotech actually divulged some good news. That news was certainly encour...

Itamar Medical (NASDAQ:ITMR) +44% on being taken over by Zoll Medical for ~$538M Leap Therapeutics (NASDAQ:LPTX) +42% to present new data from the DisTinGuish study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congres BELLUS Health (NASDAQ:BLU) +24% positive interim f...

- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - - Majority of patients experienced antitumor activity with a disease control rate of 86% - - ADP-A2M4CD8 ce...

To further consolidate its position in molecular diagnostics, Roche Holding (OTCQX:RHHBY) (OTCQX:RHHBF) has agreed to acquire German-based biotech company TIB Molbiol Group. On Thursday, Roche announced a definitive share purchase agreement to acquire 100% of outstanding shares of T...

It might have been a mixed day for the broader averages, but AMC Entertainment (NYSE:AMC) had an unambiguously good session. No, this wasn't a result of meme-stock traders attempting to force another short squeeze -- at least, not completely. Rather, AMC shares reacted to actual positive...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adaptimmune Therapeutics plc on the Rise After Entering into a Strategic Collaboration with Genentech” Adaptimmune Therapeutics (NASDAQ: ADAP) plc climbed over 23%...